Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
Go back to Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
March 8, 2021 7:04 AM EST
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $228.00 price target on Eli Lilly (NYSE: LLY) following the company's Preparing for the Donanemab Data expert conference call on Friday. After weeks of reviewing donanemab data, and multiple calls with management and Alzheimer's experts, Divan is... More
